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Abstract 
Background: In the absence of a method to culture Plasmodium vivax, the only way to source parasites is ex vivo. 
This hampers many aspects of P. vivax research. This study aimed to assess the safety of apheresis, a method for selec-
tive removal of specific components of blood as a means of extracting and concentrating P. vivax parasites.
Methods: An iterative approach was employed across four non-immune healthy human subjects in single subject 
cohorts. All four subjects were inoculated with ~ 564 blood stage P. vivax (HMP013-Pv) and subjected to apheresis 10 
to 11 days later. Blood samples collected during apheresis (haematocrit layers 0.5% to 11%) were tested for the pres-
ence and concentration of P. vivax by microscopy, flow cytometry, 18S rDNA qPCR for total parasites, and pvs25 qRT-
PCR for female gametocyte transcripts. Safety was determined by monitoring adverse events. Malaria transmission to 
mosquitoes was assessed by membrane feeding assays.
Results: There were no serious adverse events and no significant safety concerns. Apheresis concentrated asexual 
parasites by up to 4.9-fold (range: 0.9–4.9-fold) and gametocytes by up to 1.45-fold (range: 0.38–1.45-fold) compared 
to pre-apheresis densities. No single haematocrit layer contained > 40% of all the recovered P. vivax asexual parasites. 
Ex vivo concentration of parasites by Percoll gradient centrifugation of whole blood achieved greater concentration 
of gametocytes than apheresis. Mosquito transmission was enhanced by up to fivefold in a single apheresis sample 
compared to pre-apheresis.
Conclusion: The modest level of parasite concentration suggests that the use of apheresis may not be an ideal 
method for harvesting P. vivax.
Trial Registration Australia New Zealand Clinical Trials Registry (ANZCTR) Trial ID: ACTRN12617001502325 registered on 
19th October 2017. https ://www.anzct r.org.au/Trial /Regis trati on/Trial Revie w.aspx?id=37381 2.
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Background
Plasmodium falciparum is the most prevalent malaria 
parasite in Africa. However, Plasmodium vivax has a 
wider geographical distribution. In 2018, there were 
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accounting for 50% of cases in South East Asia and 75% 
of cases in the Americas [1].
In the absence of a method for continuous in vitro cul-
ture of P. vivax, parasites are usually sourced ex vivo from 
infected humans. This limits many aspects of the study of 
P. vivax research, including the development of interven-
tions to control and eliminate P. vivax, such as diagnos-
tics, drugs and vaccines. For example, a reliable source of 
P. vivax sporozoites is required to test and develop new 
drugs targeting the dormant liver-stage parasites—the 
hypnozoites. Currently this entails an expensive, logisti-
cally complex and unreliable process of sourcing P. vivax-
infected mosquitoes from endemic areas. In addition to 
the practical issues, parasites sourced in this way are not 
genetically homogenous. Thus, experiments are subject 
to possible effects of strain variability.
Experimental infection of human subjects with malaria 
termed volunteer infection studies (VIS) or controlled 
human malaria infection (CHMI) studies are increas-
ingly being used for drug and vaccine development [2–7]. 
Infections can be induced by mosquito bite, injection of 
sporozoites or blood-stage parasites. The latter is used 
in the induced blood stage malaria (IBSM) model, where 
healthy subjects are injected with Plasmodium infected 
red blood cells. The IBSM model is being increasingly 
used for clinical studies of P. vivax [7–9].
It has recently been shown that P. vivax can be success-
fully transmitted from healthy subjects to Anopheles ste-
phensi mosquitoes [9, 10]. In this study sporozoites were 
harvested from the infected mosquitoes that were able to 
infect human hepatocytes in vitro [9]. Although this sys-
tem offers the potential to study the biology of P. vivax 
malaria transmission and liver stage parasites, it is not a 
sustainable large-scale source of sporozoites for down-
stream work.
Apheresis is the removal of a specific component of an 
individual’s blood. Currently, centrifugal apheresis is the 
preferred method whereby blood components are sepa-
rated based on buoyancy. Computer-controlled auto-
mated apheresis systems undertake continuous removal, 
separation of the target component, and then return 
the remaining blood to the individual [11]. Automated 
erythrocytapheresis, also known as red cell exchange 
(RCE) has been used in the past for treatment of severe 
P. falciparum malaria with the rationale of reducing the 
parasitized red blood cell concentration by replacing 
Plasmodium-infected red blood cells with normal donor 
red blood cells [12]. However, the rapid parasite clear-
ance resulting from artesunate therapy has negated the 
need for RCE as a treatment for severe malaria [13, 14].
Reported below are the results of a P. vivax clinical 
trial where apheresis was used as a means to harvest 
and concentrate all blood stages of P. vivax, including 
gametocytes, from human subjects experimentally 
infected with blood-stage P. vivax parasites.
Methods
Study design
The study presented here is a Phase 1 exploratory study 
that was conducted in four sequential single subject 
cohorts (ANZCTR Trial ID: ACTRN12617001502325) 
and performed at Q-Pharm Pty Ltd, Brisbane, Australia 
and the Apheresis Unit at the Royal Brisbane and Wom-
en’s Hospital (RBWH), Australia between October 2017 
and May 2019. The primary objective of the study was to 
determine the safety of the P. vivax infection in healthy 
subjects following inoculation with blood-stage parasites, 
and the safety of apheresis for collection of P. vivax para-
sites from experimentally infected subjects. Secondary 
objectives were to assess the feasibility of apheresis as a 
method of harvesting, concentrating and subsequently 
cryopreserving P. vivax parasites from healthy subjects. 
Exploratory objectives were to evaluate the potential for 
apheresis to be used as a method for producing a P. vivax 
human malaria parasite bank, to evaluate the transmis-
sion of P. vivax gametocytes to mosquitoes and to collect 
and store plasma and peripheral blood mononuclear cells 
harvested using apheresis.
Specific modifications to the study protocol, such as 
the apheresis procedure, were required between sub-
jects in an attempt to optimize the procedure and meet 
the objectives. All changes made between subjects were 
based on the findings from previous subjects.
Study subjects
Healthy adult males and females, aged between 18 and 
55  years who met all inclusion criteria and none of the 
exclusion criteria were eligible for participation. Subjects 
were required to be malaria-naïve, Duffy blood group 
positive and have blood type O. Female subjects had to 
be Rh(D) positive. All subjects had to be available for a 
safety follow up period of three months. A full list of the 
inclusion/exclusion criteria for this study is included in 
the study protocol located in Additional file 1.
Study conduct
Pre‑clinical component
A pre-clinical experiment was conducted prior to the 
clinical trial in order to confirm the feasibility of harvest-
ing Plasmodium parasites using apheresis. The P. falcipa-
rum NF54 clone was used in these experiments [15] due 
to limited availability of P. vivax parasites. Plasmodium. 
falciparum infected red blood cells (17.6 ml; 16 ml blood 
with 0.1% asexual parasitaemia and 1.67  ml blood with 
0.01% gametocytaemia) were added to 450  ml of fresh 
venous whole blood and subjected to ex  vivo apheresis. 
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Samples were collected from the 1%, 2%, 3%, 5% and 
7% haematocrit (HCT) layers as determined by visual-
izing the colour saturation of the apheresis product. An 
automated haematology analyser (Sysmex XN-3000; Sys-
mex UK) was used retrospectively to confirm the HCT 
of samples collected during apheresis. Presence of para-
sites was assessed in each layer by 18S qPCR [16] and 
microscopy.
Clinical component
Following intravenous injection of P. vivax (day 0), sub-
jects were monitored by daily telephone calls until day 
4, when subjects visited the clinical unit daily until the 
day of apheresis. Subjects were monitored for adverse 
events (AEs), signs and symptoms of malaria infection, 
and blood was collected for 18S qPCR measurement of 
parasitaemia. The severity of AEs were determined by 
the common terminology of clinical trial adverse events 
(CTCAE) v. 4.03 [17].
The threshold for commencement of apheresis and 
treatment with artemether–lumefantrine was within 
24  h of a parasitaemia > 20,000 parasites/mL, or the 
Malaria Clinical Score reaching > 6 [10], or at the Inves-
tigator’s discretion. The morning that this threshold was 
reached (anticipated based on previous studies to be Day 
10 or 11 [9], subjects were admitted to the clinical unit 
(Q-Pharm) for initial safety assessments before being 
escorted to the Apheresis Unit at RBWH by Q-Pharm 
staff. The Apheresis Unit is located in the Haematol-
ogy Department at RBWH where patients are subject to 
donor or therapeutic apheresis. At the Apheresis Unit the 
subjects underwent the apheresis procedure as per the 
Standard Operating Procedure (Additional files 2, 3, 4 
and 5) whilst being supervised by the apheresis specialist 
nurse and under the supervision of the responsible clini-
cal haematologist (GK). The same apheresis nurse per-
formed the apheresis procedure for all four subjects. The 
apheresis procedure lasted 1–4  h. Subjects were then 
escorted back to the clinical unit and began treatment 
with artemether–lumefantrine (Riamet®, Novartis Phar-
maceuticals Australia Pty Ltd). Treatment consisted of 
six doses of 4 tablets at 12 hourly intervals (each tablet 
contains 20 mg artemether and 120 mg of lumefantrine). 
Subjects remained confined within the clinical unit for 
48–72  h for safety monitoring. Following release from 
confinement, subjects attended protocol specified visits 
until three months post-treatment to monitor for signs 
of recrudescent parasitaemia and to assess late safety sig-
nals. Relapse is not a concern in the P. vivax IBSM stud-
ies as liver infection is bypassed and hypnozoites are not 
produced. A schematic of the study design is shown in 
Additional file 6: Fig. S1.
This study used an iterative adaptive design approach 
where subject safety and outcome data were analysed 
after each subject and modifications made to improve the 
chances of meeting the exploratory objectives in the sub-
sequent subject. A summary of the changes instituted is 
shown in Table 1.
CMNC; continuous mononuclear cell collection, HCT; 
haematocrit. Protocols for subjects 1 to 4 and all experi-
ments can be found in Additional files 7, 8, 9 and 10. 
*Biological duplicates involved repeat 18S qPCR testing 
from two separate blood samples from each HCT layer 
collected using apheresis.
When a HCT range is included the sample was taken 
from multiple HCT layers e.g. 5–7% = 5%, 6% and 7% 
HCT. +Originally aimed to sample 8% HCT layer but 
actual sample consisted of 11% HCT. #During cohort 4 
Table 1 Summary of main study design differences between subjects
Subject 1 Subject 2 Subject 3 Subject  4#
Apheresis procedure CMNC CMNC CMNC Red cell depletion followed by CMNC 
on red cell depletion product
HCT layers sampled* 1%, 2%, 3%, 5%, 7% 1%, 2%, 3%, 5%, 7% 0.5%, 1%, 2%, 3%, 
5%, 7%, 11%+ 
2–3%, 5–7%, 
1–7%
From the primary apheresis (HCT): 
Intermediate (64%)
From the secondary apheresis (HCT): 
Final (3%) Spare (5%) Waste (42%)
Apheresis timepoint 10 10 11 PM 11 AM
Mosquito feeding assay samples Pre-apheresis (with-Percoll 










ment), Intermediate, Final, Waste
Whole blood:citrate ratio during 
apheresis
15:1 8:1 8:1 13:1
Citrate added to apheresis collec-
tion bags
No Yes Yes Yes
Biological duplicates* No No Yes Yes
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a red cell depletion was carried out, producing an inter-
mediate bag sample, followed by a second apheresis pro-
cedure on the red cell depletion product. The second 
apheresis procedure involved sampling of ~ 100  ml of 
the lowest HCT layers of the sample (final bag) followed 
by ~ 100mls of the subsequent lowest HCT layers (spare 
bag) and then the remainder ~ 100mls (waste bag).
Malaria challenge agent
The P. vivax human malaria parasite (HMP) bank 
HMP013 was derived from blood group O rhesus posi-
tive blood donated from a returned traveller from India 
who presented with clinical manifestations of malaria [9]. 
The inoculum was prepared as previously described [18].
Measurement of parasitaemia by qPCR
Parasitaemia was quantified using 18S qPCR targeting 
the highly conserved Plasmodium 18S ribosomal RNA 
gene [16, 19]. Quantitative reverse transcriptase PCR 
(qRT-PCR) assays were used to quantify gametocyte lev-
els with assays targeting the P. falciparum pfs25 (female) 
and pfMGET (male) gametocyte mRNA transcripts [20] 
and P. vivax pvs25 (female) gametocyte mRNA tran-
scripts [21].
Flow cytometry
Flow cytometry was performed to characterize cell popu-
lations present in samples collected during the apheresis 
process. A combination of stains and antibodies were 
used to identify cells containing DNA/RNA (SYBR Green 
I), white blood cells (WBCs) (CD45 antibody) and/or 
reticulocytes (CD71 antibody). Samples from subject 
1 were stained with SYBR Green I (Molecular Probes); 
samples from subjects 2 and 3 were stained with SYBR 
Green I and CD45-PacificBlue; and samples from sub-
ject 4 were stained with SYBR Green I, CD45-Pacific 
Blue and/or CD71-APC. Samples were kept on ice or at 
4–8 °C until analysed by flow cytometry.
SYBR Green I staining
A volume of 2.5 μl or 1 × 106 cells from each sample was 
stained with 30–50 μl of SYBR Green I at 10× for 30 min 
in the dark. After incubation, 200 μl of FACS buffer (2% 
fetal bovine serum in phosphate buffered saline) was 
added.
Antibody staining
Approximately 1 × 106 cells were stained with 5–10  μg/
ml of CD45-Pacific Blue or 2.5 μl of CD71 stock solution 
for 30 min at 4–8 °C in the dark. Cells were washed twice 
with PBS by centrifugation at 1455×g for 4 min, at 4 °C. 
After the last wash 200 μl of FACS buffer was added to 
the cells.
Double staining with SYBR Green I and CD45-Pacific 
Blue: A volume of 30  μl of SYBR Green I at 10× was 
added to pelleted cells that were previously stained with 
CD45-Pacific Blue (as mentioned above) for 30  min at 
4–8 °C, in the dark. After incubation a volume of 200 μl 
of FACS buffer was added.
Triple staining with SYBR Green I, CD45-Pacific Blue 
and CD71-APC: Approximately 1 × 106 cells were stained 
with 10 μg/ml of CD45-Pacific Blue, 2.5 μl of CD71 stock 
solution and 30 μl of SYBR Green I at 10x. Samples were 
incubated for 30 min in the fridge (4–8  °C) in the dark. 
Cells were washed twice with PBS by centrifugation at 
1455×g for 4 min, at 4ºC. After incubation a volume of 
200 μl of FACS buffer was added.
Flow cytometry analysis
Samples from subjects 1, 2 and 3 were acquired on a 
FACS CANTO II (BD Biosciences), using the 488 nm and 
405 nm lasers. SYBR Green I positive cells were detected 
using a 530/30  nm band-pass filter and CD45-Pacific 
Blue positive cells were detected using a 450/50  nm 
band-pass filter. Samples from subject 4 were acquired on 
a LSR FORTESSA (BD Biosciences), using the 488  nm, 
640  nm and 405  nm lasers. SYBR Green I positive cells 
were detected using a 530/30  nm filter, CD45-Pacific 
Blue positive cells were detected using a 450/50  nm fil-
ter and CD71-APC positive cells were detected using a 
670/14 nm filter. Flow cytometry data was analysed using 
FlowJo® software (version 10.8, Tree Star Inc, Oregon, 
USA).
Microscopy
Thick and thin smears were stained with Giemsa and 
examined under a 100× oil immersion objective by level 
1 or 2 WHO certified malaria microscopists. Apheresis 
samples were expected to have a significantly different 
composition in terms of proportions of RBCs and WBCs 
when compared to whole blood (e.g. RBCs make up 1% 
and approximately 46% of 1% HCT and whole blood 
samples respectively). As such, standard parasitaemia 
measures by microscopy were not feasible. It was decided 
that the expert microscopists would estimate parasitae-
mia based on sample composition.
Mosquito feeding assays
Transmissibility of pre-apheresis samples and post-
apheresis samples to An. stephensi was evaluated using 
membrane feeding assays (MFA) [9, 22]. For enriched 
MFA, gametocytes present in 80  mL of whole blood 
(pre-apheresis) were enriched in 70% Percoll gradient. 
For direct MFA (DMFA), 650µL of pellet from whole 
blood (pre-apheresis) or from each apheresis sample 
was reconstituted to 50% haematocrit with malaria naïve 
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AB + serum. Infection in midguts was assessed by qPCR 
[23] 8 days after the feeding assays. For logistic reasons, 
enriched MFA was not carried out in subject 4. Follow-
ing consideration of gametocyte levels measured by 
qRT-PCR targeting pvs25, DMFA was not carried out in 
subject 2.
Apheresis procedures
Apheresis was carried out using a Spectra Optia v11.3 
apheresis system (Terumo BCT, Inc Tokyo Japan) as 
detailed in the Additional file 11.
The continuous mononuclear cell collection procedure 
was used to sample from the targeted HCT layers from 
the blood of subjects 1 to 3. The targeted HCT layers that 
were sampled from these subjects ranged from the plate-
let rich layer through to the red cell rich layer.
A double stage procedure was used to collect the tar-
geted HCT layers from subject 4. In the first stage, a red 
cell depletion procedure was used to collect approxi-
mately 500  ml of packed red blood cells from the sub-
ject. Targeted HCT layers were then collected from the 
red cell concentrate using the polymorphonuclear (PMN) 
collection procedure. The starting product (red cell con-
centrate) for the second stage of this procedure had a sig-
nificantly higher HCT than the whole blood of subjects 
1 to 3 and sampling focussed on the higher HCT layers. 
This was the rationale for using a PMN collection in sub-
ject 4 rather than the CMNC collection used in subjects 
1 to 3.
Statistical analysis
Continuous data was summarized using descriptive sta-
tistics (mean and standard deviation, or median and 
interquartile range). Categorical data was presented 
using N and %. Descriptive statistics were produced 
using Microsoft Excel® (version 1903). GraphPad® Prism 
was used for the construction of all figures.
Results
Pre‑clinical experiment
The feasibility of extracting Plasmodium parasites from 
blood using apheresis was initially assessed using cul-
tured P. falciparum parasites. The 1% HCT layer con-
tained the greatest concentration of all parasites as 
determined by 18S qPCR, with a 1.3-fold concentration 
of all parasites and a 3.7 and eightfold concentration for 
female and male gametocytes, compared to pre-aphere-
sis (Additional file 6: Fig. S5 and Tables 1, 2 and 3). The 
2% HCT layer contained the greatest concentration of 
asexual parasites by microscopy (2.7-fold concentration; 
Additional file 6: Fig. S6A and Table S4). The highest con-
centration of gametocytes detected by microscopy was 
seen in samples collected from the 1% HCT layer (76-
fold; Additional file 6: Fig. S6A and Table S4) with stage 
1 gametocytes making up the largest proportion (37.5%). 
All stages of gametocytes apart from stage 5 gametocytes 
were visualized. Both asexual parasites and gametocytes 
were also visualized by microscopy in the 1%, 3% and 
5% HCT layers (Additional file 6: Fig. S6B and Table S5). 
These results demonstrated the technical feasibility of the 
Table 2 Summary of the main safety findings
SAE serious adverse event, AE adverse event
Summary of the main safety findings encountered during the study
Subject 1 Subject 2 Subject 3 Subject 4 Total AEs
SAEs 0 0 0 0 0
AEs 20 13 15 20 68
AEs related to malaria 13 8 14 19 54
AEs related to apheresis 2 3 0 4 9
Max temp °C 40.2 38.8 40.2 39.6 N/A
Max malaria clinical score 8 1 2 7 N/A
Ibuprofen use 400 mg × 5 400 mg × 5 400 mg × 5 nil N/A
Acetaminophen use 1 g × 4; 500 mg × 1 1 g × 2 1 g × 4 500 mg × 2; 1 g × 2 N/A
Peak ALT (IU/L) 111 118 47 80 N/A
Peak AST (IU/L) 83 57 42 44 N/A
Platelet Nadir (× 109/L) 119 98 99 75 N/A
Maximum drop in haemoglobin from 
baseline (g/L)
17 9 25 20 N/A
Lymphocyte Nadir (× 109/L) 0.33 0.43 0.58 0.75 N/A
Peak parasitaemia (parasites/mL) 15,943 35,156 64,243 44,431 N/A
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approach and the experiment was allowed to proceed to 
the clinical stage. 
Clinical experiment
The course of P. vivax infection (Fig. 1) followed the same 
course as demonstrated in previous studies [9]. Subjects 1 
and 2 were treated with artemether/lumefantrine 10 days 
post malaria inoculation. To augment pre-apheresis para-
sitaemia, treatment of subjects 3 and 4 was delayed to day 
11. Apheresis could be delayed safely as the clinical signs 
observed for subjects 3 and 4 were mild enough for the 
artemether/lumefantrine treatment, only administered 
after apheresis, to be postponed by 24  h. All subjects 
became 18S qPCR negative for parasites within 72  h of 
treatment initiation.
A summary of the key differences in the planning of the 
clinical trial in each of the four subject cohorts is shown 
in Table 1. During cohort 4 a red cell depletion was car-
ried out, producing an intermediate bag sample, followed 
by a second apheresis procedure on the red cell depletion 
product. The second apheresis procedure involved sam-
pling of ~ 100 ml of the lowest HCT layers of the sample 
(final bag) followed by 100mls of the subsequent lowest 
HCT layers (spare bag) and then the remainder (waste 
bag) (Additional file 6: Fig. S3). A schematic of the sam-
pling that occurred during cohort 4 can be seen in Addi-
tional file 6: Fig. S3.
Safety
A total of 68 AEs occurred in the 4 subjects (Table  2). 
No Serious AEs were reported. The majority of AEs were 
mild or moderate. Five severe AEs occurred in 4 subjects: 
one episode of neutropenia (0.68 × 109/L [0.45 × LLN]; 
duration 8  days), two of lymphopenia (0.43 × 109/L 
[0.43 × LLN] and 0.33 × 109/L [0.33 × LLN]; both lasting 
3 days), and two of fever (both 40.2 °C; duration 30 min 
and 25 min). All severe AEs were transient and resolved 
by the end of the study. The majority of AEs (54/68; 
79.4%) were attributed to malaria, while 9/68 (13.2%) 
were attributed to apheresis. These included neutrope-
nia (one subject nadir 0.68 × 109/L) which was recorded 
three times due to changes in severity, two cases of lym-
phopenia (nadir 0.33 × 109/L and 0.75 × 109/L) and two 
cases of leukopenia (nadir 2.2 × 109/L and 2.4 × 109/L). 
One subject had an episode of herpes labialis (herpes 
simplex virus-1 PCR positive). One subject experienced 
mild hypophosphatemia (0.70 mmol/L) of two days dura-
tion. All AEs attributed to apheresis apart from the case 
of hypophosphataemia were considered to be possibly 
related to apheresis, malaria or a combination of both.
Characteristics of samples collected by apheresis
The red blood cell counts in samples from the various 
HCT layers were generally in alignment with what would 
be expected (Additional file  6: Table  S6), except in two 
Fig. 1 Parasite growth curves. Parasitaemia as measured by 18S qPCR in all four subjects. Day 0 represents the day of inoculation. Apheresis 
occurred on day 10 for subjects 1 and 2, and day 11 for subjects 3 and 4
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subjects. In subject 2 the red blood cell counts in sam-
ples from the 2% HCT layer was closer to what would 
be expected from a 3% HCT layer and vice versa, and 
the sample from the 8% HCT sample in subject 3 had a 
HCT of 11%. The variability in expected HCT and actual 
HCT is a potential limitation and should be considered 
when designing any future studies. The cell composi-
tion of samples collected using apheresis in subjects 1 
to 3 (Additional file 6: Fig. S7A) showed an ~ 60 to 170-
fold decrease in the RBC:WBC ratio from pre-apheresis 
samples compared to apheresis samples. Among samples 
collected by apheresis from subject 4, where a double 
apheresis process was undertaken, the RBC:WBC ratio 
was close to that of the pre-apheresis sample (Additional 
file 6: Fig. S7B), with the exception of the final bag sample 
(3% HCT). Reticulocyte counts measured on the Sysmex 
analyser were the highest in subject 2: 0.23 × 109/L (refer-
ence range for whole blood: 25–120 × 109/L).
Concentration of asexual parasites
18S qPCR targets the highly conserved plasmodium 18S 
ribosomal RNA gene present in asexual parasites and 
gametocytes [14, 18]. However, based on the P. vivax life 
cycle, microscopy and P. vivax female gametocyte qRT 
PCR data (pvs25) it was determined that the vast major-
ity of parasites, detected using 18S qPCR, were asexual 
parasites.
No single HCT layer contained > 40% of all the recov-
ered P. vivax asexual parasites (Fig.  2). An increase in 
parasite concentration per ml of sample attained via 
apheresis occurred as HCT increased in subjects 1 to 3 
(Fig.  2a), with some variation in relative enrichment of 
parasites in apheresis samples compared to pre-apher-
esis samples at any given HCT (Fig.  2a). The highest 
concentration achieved was a 4.9-fold increase in para-
site density in the 7% HCT layer in subject 1 (Fig.  2a 
and Additional file  6: Table  S7). There was no apparent 
enrichment of parasites when the procedure was modi-
fied to include a second apheresis process (subject 4; 
Fig. 2b).
When parasite concentration was adjusted for RBC 
count, all apheresis samples collected from subjects 1 to 3 
demonstrated enrichment for asexual parasites compared 
to pre-apheresis (Additional file 6: Fig. S2A). In general, 
when parasite counts were corrected for RBC count, par-
asite enrichment was highest in the samples collected at 
the lower HCT (Additional file 6: Fig. S2 and Table S7). 
The relative concentration of parasites from subject 4, 
where the second apheresis procedure was performed, 
was observed in the lowest HCT samples. In particu-
lar, the final bag (3% HCT) and the spare bag (5% HCT) 
samples had relative enrichment levels of 20- and 8-fold 
respectively compared to pre-apheresis (Additional file 6: 
Fig. S2 and Table S7).
Concentration of P. vivax gametocytes
Analysis of the apheresis samples from subject 4, where 
the double apheresis process was undertaken, demon-
strated an increase in the level of female gametocytes 
of 1.45-fold per ml in the apheresis sample compared 
to a venous blood sample collected pre-apheresis, as 
a b
Fig. 2 Fold enrichment of parasites/ml determined by 18S qPCR. Fold enrichment of parasites as determined by 18 qPCR in samples collected 
using apheresis compared to the pre-apheresis samples in subjects 1 to 3 (a) and subject 4 (b)
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determined by qRT PCR for the gametocyte-specific tran-
script pvs25 (Fig. 3b and Additional file 6: Table S8).
Subjects 1, 2 and 3 demonstrated a reduction in the 
level of female gametocytes compared to pre-apheresis 
(Fig. 3a and Additional file 6: Table S8). In most cases the 
reduction was > 10-fold. Percoll concentration of whole 
blood taken pre-apheresis resulted in a significant enrich-
ment (up to 45-fold in subject 3) of pvs25 compared to 
pre-apheresis samples not enriched with Percoll (Fig. 3c 
and Additional file 6: Table S8).
In subject 1 the Percoll enrichment experiment failed 
due to technical issues resulting from suboptimal pro-
cessing of the sample.
When gametocyte concentrations were corrected for 
red blood cell counts, enrichment levels were generally 
higher in the lower HCT samples (Additional file 6: Fig. 
S4a, b and Table S8). Relative enrichment of gametocytes 
in subjects 1, 2 and 3 was lower than for total parasites, 
with a maximum enrichment of 6.2-fold in the 0.5% HCT 
layer (Additional file  6: Table  S8). In subjects 3 and 4 
enrichment relative to red blood cell count was observed 
(Additional file  6: Fig. S4A, B). In subject 4, the great-
est enrichment of gametocyte transcripts in the dou-
ble apheresis process was observed in the spare bag (5% 
HCT) with an enrichment of 6.1-fold (Additional file  6: 




Fig. 3 Fold enrichment female P. vivax gametocytes determined by pvs25/ml. Fold enrichment of female P. vivax gametocytes determined by pvs25/
ml in samples collected using apheresis compared to the pre-apheresis sample in subjects 1, 2 and 3 (a) and subject 4 (b). Fold enrichment of 
female P. vivax gametocytes determined by pvs25/ml in samples collected using apheresis compared to the pre-apheresis sample and pre-apheresis 
samples enriched with Percoll in subjects 1, 2 and 3 (c)
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Flow cytometry
In subjects 2 and 3, it was observed that as sampling was 
undertaken from progressively lower haematocrits there 
was an increase in the percentage of WBCs (Additional 
file  6: Figs.  S10 and S11). A small percentage of SYBR 
Green I + and CD45- cells, which could represent either 
parasitized RBCs or reticulocytes, were detected in sam-
ples from subjects 2 and 3 (Fig.  4a, b); pooled samples 
collected at 2–3% HCT from subject 3 had the highest 
concentration (0.59%) of SYBR Green I + and CD45-cells 
(Fig. 4b). In subject 4, where CD71 antibody staining was 
used to identify reticulocytes, the highest levels of reticu-
locytes (CD71 + cells) were observed in the final bag (3% 
HCT) and the spare bag (5% HCT) (Fig. 4c). Microscopic 
analysis of these samples suggested that the reticulo-
cyte population detected by flow cytometry consisted of 
uninfected reticulocytes. No parasitized RBCs or reticu-
locytes could be detected by flow cytometry, and thus 
indicating that these cells are absent or below the limit of 
detection by flow cytometry.
Microscopy
The high concentration of WBCs in apheresis samples, 
meant many of the thick and thin blood smears were 
extremely difficult to read (Additional file  6: Tables S9 
and S10). Among samples where it was possible to read 
the films, parasite counts were low, and in alignment 




Fig. 4 Flow cytometry cohorts 2 to 4. Percentage of CD45-/SYBR + in samples obtained from subject 2 (a) and subject 3 (b). The percentage of 
(CD71 +) reticulocytes from subject 4 (c)
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Tables S9 and S10). Notwithstanding the technical diffi-
culties in reading the slides and the low parasite counts, 
no apparent concentration of parasites was observed in 
any of the apheresis samples compared to pre-apheresis. 
The 3% HCT sample in subject 3 contained 7 parasitized 
cells compared to 0 in the pre-apheresis sample and the 
1% HCT sample in subject 1 demonstrated a fourfold 
increase in the number of visualized parasites compared 
to pre-apheresis. In general, higher parasite numbers 
were seen in the lower HCT layers. The vast majority 
of parasitized RBCs contained ring form parasites, with 
trophozoites and gametocytes observed in samples from 
subjects 3 and 4 only (Additional file  6: Tables S9 and 
S10).
Mosquito transmission
Membrane feeding of pre-apheresis or post Percoll 
enrichment samples were undertaken in all 4 subjects, 
but for logistical reasons membrane feeding on apher-
esis samples could only be undertaken in subjects 1 and 
4 (Table 3).
None of the samples from subject 1 or 2 resulted in 
successful mosquito transmission (Table  3). In subject 
3, the infection rate from the Percoll-enriched sample 
was 5.8-fold higher than the infection rate from the non-
enriched pre-apheresis sample (99% vs 17.2% [Table 3]). 
Likewise, in subject 4, the infection rate from the final 
bag (3% HCT) was 5.5-fold higher than the infection rate 
from either the pre-apheresis sample or the intermediate 
bag (64%HCT) (pre-apheresis: 3.6%, intermediate bag: 
4%, final bag: 20% [Table 3]).
The final sample bag (3% HCT) in subject 4 was the 
only sample obtained using apheresis that demonstrated 
an increase in transmission over samples obtained pre-
apheresis. Due to logistic issues the spare bag (5% HCT), 
which contained the greatest enrichment for gameto-
cytes compared to pre-apheresis when adjusted for red 
cell counts in subject 4 (Additional file  6: Fig. S4b) was 
not subject to membrane feeding.
Additional 18S qPCR testing
To investigate for possible accumulation of parasites in 
the magnets and tubing structures in the apheresis cas-
sette, qPCR testing was carried out on three blood clots 
with diameters of up to 1  cm found near two magnets, 
and a silo like structure that formed part of the single 
use apheresis tubing and processing cassette from sub-
ject 3 (Additional file 6: Fig. S13). Clots were thoroughly 
homogenized and tested by 18S qPCR. The greatest 
enrichment observed relative to pre-apheresis whole 
blood was 1.4-fold in the apheresis cassette magnet 2 
sample (Additional file 6: Fig. S14 and Table S11).
To investigate whether haemolysis may be taking place 
in the apheresed blood resulting in release of parasite 
DNA into the extracellular fluid, plasma from apheresis 
samples in subject 3 was collected by centrifugation of 
the sample, with the plasma subject to 18S qPCR testing. 
However, no significant accumulation of parasite DNA 
was detected in the plasma compared to pre-apheresis 
(Additional file 6: Fig. S14 and Table S11).
Discussion
Using apheresis it was possible to achieve modest con-
centration of both asexual and gametocyte stages of P. 
vivax. However, the modest level of parasite enrichment 
(4.9-fold and 1.45-fold for asexual parasites and game-
tocytes respectively) was deemed to be insufficient for 
downstream research. Furthermore the relatively low 
parasite levels, particularly of gametocytes, meant that 
the figures may be subject to chance variations in parasite 
levels.
Results of this study suggest that apheresis in healthy 
subjects infected with blood-stage P. vivax parasites is 
safe. No serious adverse events were encountered, with 
all adverse events having resolved by the end of study. 
The majority of adverse events were malaria related, and 
in line with previous P. vivax IBSM studies [7, 8]. Adverse 
events related to apheresis consisted largely of asympto-
matic transient reductions in haematology parameters.
After correction for red blood cell number, parasite 
quantitation by qPCR suggested that both asexual para-
sites and gametocytes were preferentially concentrated 
in the lower HCT layers (Additional file  6: Figs. S2 and 
S4). Furthermore, the pre-clinical experiment demon-
strated a selective concentration of P. falciparum gameto-
cytes compared to asexual parasites in lower HCT layers 
(Additional file  6: Fig.  S6A and Table  S4). However as 
the pre-clinical experiment did not involve collection of 
blood from an infected subject they do not fully replicate 
those collected ex vivo, for example being subject to host 
interactions such as sequestration, thus limiting the util-
ity of this work in predicting what would be the situation 
in natural infection. Findings from the pre-clinical and 
clinical experiments were consistent with the previously 
published observations of the buoyancy of Plasmodium 
parasites [24].
Several scenarios were considered to explain why 
concentration of parasites using apheresis was lower 
than expected. Firstly, as gametocyte concentrations in 
apheresis samples were around the level of detection of 
the pvs25 by qRT-PCR, minor variation in concentra-
tion may have been difficult to quantify [25]. Secondly, 
infected RBCs containing magnetic haemozoin [26] may 
have attached to ferromagnetic components of the apher-
esis apparatus. Thirdly, it is possible that lysis of asexual 
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parasites and gametocytes occurred during the apher-
esis procedure. This latter hypothesis is supported by a 
recent report suggesting that parasite maturation results 
in increasing fragility of P. vivax infected red blood cells 
[27]. Although it may have been possible to assess for low 
level haemolysis during the procedure, for example by 
measuring haptoglobin levels, controlling for a range of 
other variables would have been difficult.
An enhanced level of transmission to mosquitoes com-
pared to whole blood samples collected pre-apheresis 
was only observed on one occasion (final sample bag [3% 
HCT] in subject 4), corresponding to the higher game-
tocyte concentration in this sample compared to the 
pre-apheresis whole blood (Fig.  4b). A possible expla-
nation of the low success in the transmission studies 
was the difficulty in maintaining tight temperature con-
trol to prevent exflagellation of male gametocytes [28], 
thereby negatively impacting gametocyte infectivity [29]. 
Blood was most vulnerable to a temperature drop whilst 
in the apheresis equipment itself. It was not possible to 
heat apheresis equipment, and it was deemed impracti-
cal to heat the room where apheresis took place to > 35 
°C. Temperature monitoring was not possible during the 
experiments. However, the demonstration of transmis-
sion success in the final bag (3% HCT) indicates that at 
least some gametocytes were maintained within a tem-
perature range that did not trigger exflagellation. Regard-
less of the underlying cause, recent reports of success in 
improving concentration of gametocytes and enhanced 
transmission by either Percoll [9, 10] or magnetic bead 
[30] enrichment suggests that such methods are superior 
for concentration of gametocytes for mosquito transmis-
sion experiments.
Each of the vials from the HMP bank used in this study 
to infect subjects contain 2.08 × 106 parasites. Based on 
the greatest level of asexual enrichment per ml of sample 
observed (7% HCT, subject 1), calculations suggest that 
apheresis alone can create parasites vials with a maxi-
mum of 7.92 × 104 parasites (Additional file 6). Therefore, 
to create a HMP bank using an apheresis approach equiv-
alent to the one used to infect volunteers in this study 
a > 25-fold increase in pre-apheresis parasitaemia would 
be required, equating to > 650,000 parasites/ml. Attain-
ing such high parasitaemia would likely lead to signifi-
cant discomfort in study volunteers, and therefore raise 
significant ethical concerns. Therefore, unless significant 
improvements in enrichment can be attained, apheresis 
should not be used to create HMP banks, and the current 
practice of collecting blood by venesection is preferable.
Strengths of the study include the wide sampling across 
HCT layers (1%, 2%, 3%, 5% and 7%) and the use of mul-
tiple methods to enumerate parasites (flow cytometry, 
microscopy and qPCR). Although only a small number 
of subjects were studied using this approach, the lack of 
promising data meant that continuation of the trial was 
deemed inappropriate by the safety review team and the 
study was terminated.
Conclusion
Given the moderate levels of enrichment and the signifi-
cant ethical, financial and logistical concerns surrounding 
P. vivax IBSM studies, it was decided that further apher-
esis studies are not warranted at this point. If apheresis 
were to be used again in the context of Malaria VIS, it 
should ideally only be carried out in subjects with normal 
haematological parameters at screening to avoid poten-
tial complications or the need for blood transfusion.
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